Immunodiagnostic Systems Hldgs PLC Trading Statement (4377Q)
18 Ottobre 2019 - 5:35PM
UK Regulatory
TIDMIDH
RNS Number : 4377Q
Immunodiagnostic Systems Hldgs PLC
18 October 2019
H1 Trading Update
Immunodiagnostic Systems Holdings PLC
18 October 2019
Immunodiagnostic Systems Holdings plc
H1 Trading Update
Immunodiagnostic Systems Holdings PLC ("IDS" or "the Group"), a
specialist producer of manual and automated diagnostic testing kits
and instruments for the clinical and research markets, today
provides a trading update for the six months ended 30 September
2019 ("H1 FY20").
Unaudited Group revenues for H1 FY20 are expected to be
GBP18.8m, 2% higher than the same period last year. On a like for
like basis ("LFL"), that is at constant exchange rate and scope,
Group revenues are in line with the same period last year.
Revenue Performance in H1 FY20
The table below summarizes the unaudited revenue performance of
the core segments of the Group. The right-hand column shows
developments in FY19 vs. FY18 to provide a view of the underlying
momentum.
Revenue LFL Change
H1 FY20 H1 FY20 v FY19 v FY18
H1 FY19
----------------------- ----------------------- -------------------------
Group GBP18.8m 0% 1%
----------------------- ----------------------- -------------------------
Automated Business GBP11.0m 0% -1%
----------------------- ----------------------- -------------------------
Automated 25-OH Vitamin
D GBP2.3m -20% -13%
----------------------- ----------------------- -------------------------
Speciality - IDS GBP7.1m 5% 1%
----------------------- ----------------------- -------------------------
Speciality - Partners GBP0.9m 52% 31%
----------------------- ----------------------- -------------------------
Instrument Sales and
Service GBP0.7m 3% 2%
----------------------- ----------------------- -------------------------
Manual Business GBP5.7m -8% -1%
----------------------- ----------------------- -------------------------
Technology Business GBP2.1m 32% 32%
----------------------- ----------------------- -------------------------
Automated business
Automated revenue remained unchanged LFL versus H1 FY19, with
growth in speciality assays offsetting declining 25-OH Vitamin D
sales.
25-OH Vitamin D revenue declined 20% LFL due to a reduction in
25-OH Vitamin D assay volumes and the impact of "Vitamin D only"
instrument returns in the US during the second half of FY19.
Speciality - IDS revenues grew by 5% LFL versus H1 FY19, with
improved performance across most indication areas, particularly our
bone and growth panels, aided by instrument placements at the end
of FY19 becoming operational. This is an improvement in trajectory
versus Q1, where this business stream declined 2% LFL versus the
prior year. We believe we can improve the growth trajectory of this
segment as we release new endocrinology assays, which is key to our
mid and long-term profitability.
Speciality - Partners revenue encompasses the sales of assays
developed by IDS's partners and sold under the IDS brand. These
consist of 51 assays in the fields of Autoimmunity and Infectious
Disease. Revenue in this segment grew by 52% LFL, a further
acceleration in the growth rate compared to the previous year. This
Autoimmune speciality segment is a key focus area for new
placements in FY19 and FY20.
The other KPIs in this business unit developed as follows:
a) We did not release any new assays in H1 FY20. The R&D
team delivered a successful performance
improvement to a key existing assay. We are targeting the release of two new assays in H2.
b) Instrument placement performance improved as set out in the table below:
H1 FY20 H1 FY19
Gross placements in Direct
Markets [1] 18 15
-------- --------
Returns in Direct Markets (14) (12)
-------- --------
Net Placements in Direct
Markets 4 3
-------- --------
Sales in Distribution Markets
[2] 14 13
-------- --------
Total Gross Instrument Sales
/ Placements [1]+[2] 32 28
-------- --------
During H1 FY20 the Group lost a significant customer which ran
one assay in high volumes across multiple analysers. This adversely
impacted the number of returns in H1. We expect assay returns in H2
to be lower than H1.
c) The average number of assays run per instrument increased to
5.4 (H1 FY19: 4.8), reflecting successful cross-selling, in
particular the adoption of Autoimmune and Infectious Disease assays
across the IDS installed based.
Manual business
The Manual business saw a decline of 8% LFL versus H1 FY19. The
decline is mainly due to a large one-off sale in H1 FY19 which was
not repeated and does not suggest systematic deterioration of the
underlying business unit performance. Thus, our goal is to improve
the revenue trajectory of this business as we move through the
second half of the year.
Technology business
Our technology business - comprising the sale of instruments and
consumables to OEM partners - continues to grow, with LFL growth of
32% versus H1 FY19, generated mainly from two active OEM partners.
We are currently in negotiations with several leads who are
interested in using the IDS analyser technology on an OEM basis,
and successful conclusion of these deals will allow us to diversify
and continue to grow this business.
Other KPIs
Closing cash and cash equivalents were GBP28.1m at 30 September
2019 (30 September 2018: 27.8m, 31 March 2019:
GBP27.7m). During H1 FY20 a dividend of GBP0.2m was paid and there were no share buybacks.
At 30 September 2019 the Group employed 273 people on a
full-time employment basis (30 September 2018: 286 persons, 31
March 2019: 283 persons).
Outlook
Based on the positive momentum within H1 we maintain our FY20
target of delivering increased full year revenue on a LFL basis
versus FY19.
For further information:
Immunodiagnostic Systems Holdings plc Tel : +44 (0)191 5190660
Jaap Stuut, Chief Executive Officer
Paul Martin, Group Finance Director
Peel Hunt LLP Tel : +44 (0)207 418 8900
James Steel
Oliver Jackson
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TSTZMMMGDRMGLZM
(END) Dow Jones Newswires
October 18, 2019 11:35 ET (15:35 GMT)
Grafico Azioni Immunodiagnostic Systems (LSE:IDH)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Immunodiagnostic Systems (LSE:IDH)
Storico
Da Apr 2023 a Apr 2024
